Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Operations: 2019-2025

Historic Cash from Operations for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to $50.4 million.

  • Legend Biotech's Cash from Operations rose 186.65% to $50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$170.1 million, marking a year-over-year decrease of 7.91%. This contributed to the annual value of -$178.1 million for FY2024, which is 59.48% up from last year.
  • As of Q3 2025, Legend Biotech's Cash from Operations stood at $50.4 million, which was up 245.54% from -$34.6 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Cash from Operations peaked at $50.4 million during Q3 2025, and registered a low of -$143.0 million during Q1 2023.
  • For the 3-year period, Legend Biotech's Cash from Operations averaged around -$56.8 million, with its median value being -$58.1 million (2024).
  • As far as peak fluctuations go, Legend Biotech's Cash from Operations crashed by 14,743.51% in 2023, and later soared by 186.65% in 2025.
  • Quarterly analysis of 5 years shows Legend Biotech's Cash from Operations stood at -$69.5 million in 2021, then climbed by 28.48% to -$49.7 million in 2022, then tumbled by 92.28% to -$95.6 million in 2023, then increased by 14.18% to -$82.1 million in 2024, then skyrocketed by 186.65% to $50.4 million in 2025.
  • Its last three reported values are $50.4 million in Q3 2025, -$34.6 million for Q2 2025, and -$103.8 million during Q1 2025.